J&J CFO on Earnings, Immunology Portfolio and Pricing Pressure

The video discusses Johnson & Johnson's performance, focusing on oncology and immunology's role in driving results. It addresses the impact of biosimilars and generics, portfolio management strategies, and pricing trends. The company navigates challenges like competition and legislative pressures while maintaining growth and innovation.

What was the financial disconnect mentioned in the first section?

• $50 million

• $40 million

• $30 million

• $20 million

Which product in immunology showed significant growth?

• Tremfya

• Darzalex

• Imbruvica

• Crohn's Disease

What is the expected benefit of the new Darzalex formulation?

• Lower cost

• Increased efficacy

• Reduced side effects

• Shorter infusion time

How much impact did biosimilars have on Johnson & Johnson's financials?

• $1 billion

• $2 billion

• $3 billion

• $4 billion

What is Johnson & Johnson's strategy for dealing with underperforming businesses?

• Expand product lines

• Reduce workforce

• Sell the assets

• Increase investment

What is the average annual price reduction for Johnson & Johnson products over the last three years?

• 2%

• 3%

• 5%

• 4%

What economic factor is causing increased price negotiation in the pharmaceutical industry?

• Free market competition

• Technological advancements

• Globalization

• Government regulations